Apple has successfully appealed for the resumption of sales of its latest smartwatch models in the US. This development follows a temporary halt in sales due to a patent dispute.
The US had previously ceased the import and sale of Apple’s Series 9 and Ultra 2 smartwatches, citing concerns over patented technology used for monitoring blood-oxygen levels.
Masimo, a medical device company, had alleged that Apple infringed on its technology and hired away its staff.
Despite the White House’s refusal to lift the ban on the Series 9 and Ultra 2 watches earlier this week, Apple voiced strong opposition to the decision.
In a swift move, Apple approached the US Court of Appeals with an emergency petition, which resulted in the overturning of the sales prohibition.
In anticipation of potential legal challenges, Apple had proactively withdrawn these models from its US website and stores earlier in the month. However, sales in other regions remained unaffected.
The original ban by the US International Trade Commission (USITC), declared in October, underwent a 60-day presidential review period, concluding on Christmas Day. The White House, represented by the office of US Trade Representative Ambassador Katherine Tai, ultimately upheld the USITC’s decision following thorough consultations.”
#AppleSmartwatchSales, #USPatentDispute, #TechLegalBattles, #InnovationControversy
